Sanofi Highlights Beyfortus Effectiveness Against RSV in Infants

Sanofi, a global healthcare leader, showcased new data on Beyfortus (nirsevimab) at IDWeek 2024 in Los Angeles. The data underline the drug's effectiveness in protecting infants from respiratory syncytial virus (RSV) and related hospitalizations. Beyfortus's real-world efficacy consistently exceeds 80% in its first year.

Sanofi is expanding its Beyfortus supply with a newly approved manufacturing line in the US, Canada, and Europe. A third line is expected to further enhance supply, pending approval from the US FDA.

Nirsevimab studies presented at IDWeek include analyses of its impact in various countries. These studies confirm significant reductions in RSV-related hospitalizations and changes in clinical diagnoses.